Intro

This chapter delves into Velazodone, or Viibryd, focusing on its classification as a serotonin partial agonist and reuptake inhibitor. The discussion includes its FDA approval for major depressive disorder, economic implications post-patent expiration, and its efficacy relative to traditional SSRIs.